BIO-Europe 2026 has ended. This guide stays up as the record of who was there. See upcoming conferences

Investors at BIO‑Europe 2026

Nov 9–11, 2026 Cologne, Germany ~5.8k attendees Website

51 investors are at BIO-Europe 2026 — 58 presentations on the program. Most represented: Sofinnova Partners (4 on the program), Jeito Capital (3 on the program), Andera Partners (2 on the program). 43 of them have their own page in this guide. As of Nov 10, 2026.

All 473 organizations at BIO-Europe 2026 →

Track
Top represented
Showing 1–15 of 51 organizations
OrganizationBIO-Europe 2026 Attendance
Sofinnova Partners
Paris, France
Investors & finance
Life sciences venture capital firm investing from seed to late stage in biotech, medtech and industrial biotech.
Panel
Mon Nov 9
16:00–16:45
Cell and Gene Therapy: What Should You Know?
Where gene therapies stand across diseases, and what shifting funding and partnerships mean for regulation, manufacturing, investment and market access.
with BioM, VeonGen Therapeutics
Panel
Mon Nov 9
16:00–16:45
Fuelling Innovation: The State of Early-Stage Investment in Biotech
Investors and founders discuss how young biotech startups raise early funding today and how venture investors' priorities are shifting.
with European Innovation Council, Eir Ventures, High-Tech Gründerfonds +2 more
Panel
Tue Nov 10
15:00–15:45
Scaling Success: The Dynamics of Late-Stage Investment in Biotech
How investors back biotechs whose products are close to market, from regulatory hurdles and scaling up to going public or being acquired.
with Camarco, BNP Paribas Asset Management, TVM Capital Life Science +2 more
Jeito Capital
Paris, France
Investors & finance
Paris-based private equity investor financing biotech and medical innovation companies.
Panel
Tue Nov 10
16:00–16:45
At the Board Table: Navigating Power Dynamics and Building Senior Stakeholder Trust (In collaboration with YVC)
How younger executives and junior investors on biotech boards can earn senior members' trust and help drive decisions.
with Syncona, LifeArc, Vivet Therapeutics +1 more
Panel
Tue Nov 10
15:00–15:45
Scaling Success: The Dynamics of Late-Stage Investment in Biotech
How investors back biotechs whose products are close to market, from regulatory hurdles and scaling up to going public or being acquired.
with Camarco, BNP Paribas Asset Management, TVM Capital Life Science +2 more
Andera Partners
Paris, France
Investors & finance
Private equity firm whose life sciences team invests in biotech and medtech companies through its BioDiscovery funds.
Keynote
Mon Nov 9
12:00–13:00
Building a competitive and impactful European biotech community: Perspectives from the European Life Sciences Coalition, Argenx and Tubulis
How Europe can keep biotech talent, money and companies at home by drawing in big investors, speeding regulation and building stronger stock markets.
with Evaluate, Angelini Ventures, Tubulis +1 more
Ecosystem InnovationBusiness of Biotech
Panel
Mon Nov 9
14:00–14:45
Voices from the IPO Class of ’25/’26: What’s Next?
Leaders of biotechs that listed on the stock market in 2025 and 2026 describe life after going public and the hurdles they face.
with European Biotechnology Magazine, HealthCap, Agomab Therapeutics
AV
Investors & finance
Corporate venture capital arm of Angelini Industries, investing in biotech, medtech and digital health companies.
Keynote
Mon Nov 9
12:00–13:00
Building a competitive and impactful European biotech community: Perspectives from the European Life Sciences Coalition, Argenx and Tubulis
How Europe can keep biotech talent, money and companies at home by drawing in big investors, speeding regulation and building stronger stock markets.
with Evaluate, Andera Partners, Tubulis +1 more
Ecosystem InnovationBusiness of Biotech
Panel
Tue Nov 10
17:00–17:45
Resilient by Design: Reinventing Biopharma Alliances in a Fragmenting World
How drug companies are reshaping research and manufacturing partnerships to stay reliable as political tensions and supply chain risks divide the world.
with Handelsblatt, Circio, Evotec +1 more
Business of BiotechBiomanufacturing Strategy
Investors & finance
Italian venture capital firm investing in early-stage biotech companies.
Panel
Tue Nov 10
14:00–14:45
Immunology under the microscope: New frontiers
What is new in drugs for autoimmune and inflammatory diseases: emerging targets, recent trial results, and where companies are investing and partnering.
with MRM Health, Hansa Biopharma, Merck KGaA
Panel
Wed Nov 11
09:00–09:45
Beyond the inhaler: The respiratory market
New drugs and targets for asthma, chronic obstructive lung disease and pulmonary fibrosis, and where investors and partners are now putting money.
with Chiesi, Vicore Pharma, Novo Holdings
Investors & finance
European venture capital firm investing in technology and health companies.
Panel
Mon Nov 9
16:00–16:45
Fuelling Innovation: The State of Early-Stage Investment in Biotech
Investors and founders discuss how young biotech startups raise early funding today and how venture investors' priorities are shifting.
with European Innovation Council, Eir Ventures, High-Tech Gründerfonds +2 more
Panel
Wed Nov 11
11:00–11:45
AI-Powered Ecosystems: Transforming Drug Discovery Through Digital Collaboration
How drug, biotech and tech companies can build AI partnerships, and why AI finds easier wins in early discovery than in later clinical stages.
with 59 North Communications, OKG Capital, endogene.bio +1 more
European Investment Bank
Luxembourg, Luxembourg
Investors & finance
The European Union's lending institution, providing loans and venture debt, including to life sciences companies.
Panel
Tue Nov 10
14:30–14:55
Investing in Women’s Health: How Can Europe Scale Innovation?
How Europe can grow investment in women's health, previewing a European Investment Bank study of the field's research, unmet needs and funding options.
with European Commission
Panel
Tue Nov 10
11:15–12:15
Women’s Health: Healthcare’s Largest Underserved Market and Biggest Growth Opportunity
Why women's health is a large, neglected market, and how much value is lost when medicine is designed around the wrong default patient.
with Eir Accelerator, Women's Health Fund, Eli Lilly +2 more
Therapeutic InsightsBusiness of Biotech
Flagship Pioneering
Cambridge, MA
Investors & finance
Company-creation firm that founds, builds and funds biotech companies.
Panel
Mon Nov 9
17:00–17:45
AI in the Lab: Why Greater Efficiency Could Mean More Drugs, Not Fewer Scientists
Whether AI can speed drug development, not just discovery, how it is changing clinical trials, and whether it will replace some scientists.
with Evaluate, Ingenix
Ecosystem InnovationBusiness of Biotech
Panel
Wed Nov 11
09:00–09:45
How is the APAC region reshaping global biopharma?
How China, Japan, South Korea and other Asia-Pacific countries are moving from making drugs to inventing them, and how Western firms can partner.
with Informa, MSD, Sinovoy Health Group +1 more
HealthCare Royalty
Stamford, CT
Investors & finance
Royalty and structured-credit investor financing late-stage and commercial biopharmaceutical companies.
Panel
Tue Nov 10
16:00–16:45
Capital, Creativity, and Optionality: The New Anatomy of Life Sciences Transactions
How biotechs raise money by selling rights to future drug sales, spinning off new companies, or going public by merging with a listed one.
with Ropes & Gray, Astellas, Regeneron
Panel
Wed Nov 11
11:00–11:45
Funding Outside the Box: Alternative Financing Strategies for Startups
Ways biotech startups can raise money besides venture investors, such as loans or selling a share of future sales, and when each fits.
with BioXconomy, Claret Capital Partners, OrbiMed
AP
Asabys Partners
Barcelona, Spain
Investors & finance
Venture capital firm investing in healthcare and life sciences companies.
Panel
Tue Nov 10
15:00–15:45
Longevity – Are we getting younger?
What recent research shows about treatments that could slow or reverse aging, and how investment in this young field is taking shape.
with Longevity.Technology, Chrysea, LinkGevity +1 more
Seroba
Dublin, Ireland
Investors & finance
European venture capital firm investing in biotech and medtech companies, mainly at seed and Series A.
Panel
Mon Nov 9
14:00–14:45
ADCs in oncology: What does the data show?
What the latest data show on how well and how safely antibody–drug conjugates treat cancer, and which technologies and targets attract investors.
with GSK, Columbus Venture Partners, Oxford BioTherapeutics +1 more
Investors & finance
Venture capital firm investing in clinical-stage biotherapeutics companies in Europe and the US.
Panel
Mon Nov 9
16:15–17:00
Building the Next Global Biotech Hubs: What Makes an Innovation Ecosystem Work?
What makes a region a strong biotech hub, from talent, labs and funding to links with global drug companies.
with 59 North Communications, Gateway Factory, CSL Behring +1 more
Investors & finance
Venture investor based in Belgium and the US that backs companies developing medicines from new science.
Panel
Mon Nov 9
16:00–16:45
Fuelling Innovation: The State of Early-Stage Investment in Biotech
Investors and founders discuss how young biotech startups raise early funding today and how venture investors' priorities are shifting.
with European Innovation Council, Eir Ventures, High-Tech Gründerfonds +2 more
Talk
Mon Nov 9
09:00–10:00
Pitch, Present, Persuade: Become a Powerful Corporate Communicator
Practical ways to build a personal brand, tell memorable stories, simplify complex messages and give persuasive presentations, in person and on video.
with Optimum Communications, AmacaThera, Optimum Strategic Communications +1 more
LifeArc
London, United Kingdom
Investors & finance
UK medical research charity that funds translational research and invests in early-stage life sciences companies through LifeArc Ventures.
Panel
Tue Nov 10
16:00–16:45
At the Board Table: Navigating Power Dynamics and Building Senior Stakeholder Trust (In collaboration with YVC)
How younger executives and junior investors on biotech boards can earn senior members' trust and help drive decisions.
with Syncona, Vivet Therapeutics, Neohla Bio +1 more
Panel
Tue Nov 10
10:00–10:45
Cardiometabolic innovations beyond GLP-1 – Where are we now?
Which drug approaches beyond GLP-1 medicines are drawing attention for obesity, diabetes and heart disease risk, and where money and partnerships are going.
with Atrogi, IsomAb, V-Bio Ventures +2 more
M Ventures
Amsterdam, Netherlands
Investors & finance
Corporate venture capital arm of Merck KGaA, investing in healthcare, life science and electronics start-ups.
Talk
Mon Nov 9
15:00–16:15
Merck's EMEA Advance Biotech Grant Program
Five young biotech companies pitch their science to Merck, competing for a grant that helps them bring a product to market.
with Merck KGaA, Stemmatters, ConvEyXO +4 more
Panel
Mon Nov 9
11:15–12:00
Unlocking Pharma’s Productivity Potential
Why developing medicines keeps getting costlier and slower, and whether AI and research sourced from other companies can make drug companies more productive.
with Norstella, Blackstone Life Sciences, Novo Nordisk +1 more
Business of Biotech

Explore the full BIO-Europe 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Cologne. Leave your work email and we’ll be in touch.

Privacy

Download the full BIO-Europe 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find buyers from investors

Tell us what you sell and we’ll find the people at these investors most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Browse BIO-Europe 2026 by

Not affiliated with or endorsed by BIO-Europe or its organizers. Submit a correction